Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy
VANCOUVER, BC, May 30, 2024 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX:NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Health Canada has approved the Company’s Clinical Trial Application to examine the feasibility of a group model in MDMA-assisted psychotherapy enrolling trainee practitioners as participants.
Related news for (NUMIF)
- Numinus Wellness Inc. Announces CFO Transition
- Numinus Wellness Inc. Announces Strategic Wind-Down of Non-Operating Subsidiaries
- Numinus Wellness Announces Corporate Update
- Numinus Wellness Closes Sale of Clinics and Launches Initiative to Increase Access to Mental Health Care
- Numinus Wellness Announces Sale of Clinics and Unique Data Partnership to Increase Access to Mental Health Care